Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov Web site. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
(Posted: 11/30/2004, Updated: 06/13/2008) - In this study, researchers are testing a procedure called hyperthermic isolated hepatic perfusion to treat inoperable liver metastases secondary to ocular melanoma.
Immunotherapy for Advanced Pancreatic Cancer
(Posted: 04/25/2006, Updated: 06/13/2008) - In this trial, researchers are using a monoclonal antibody called MDX-010 to treat patients with advanced pancreatic cancer. MDX-010 binds to and blocks the activity of an immune response inhibitor molecule called CTLA-4.
More Effective Treatment for Colorectal Metastases to the Liver
(Posted: 03/22/2005, Updated: 06/13/2008) - In this phase II study, researchers are using a surgical procedure known as isolated hepatic perfusion (IHP) to deliver melphalan, an anticancer drug, directly to the liver while avoiding unnecessary systemic toxicity.
Defining Therapy for Recurrent Platinum-sensitive Ovarian Cancer
(Posted: 06/10/2008) - In this phase III clinical trial, women with platinum-sensitive, recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer will be randomly assigned to undergo secondary cytoreductive surgery, if they are candidates for such surgery, and then randomly assigned to chemotherapy with or without bevacizumab. Women who aren't surgical candidates will be randomized to chemotherapy with or without bevacizumab.
Selenium to Prevent Recurrence of Colorectal Polyps
(Posted: 05/27/2008) - In this trial, patients who have a history of colorectal adenoma--noncancerous growths (polyps) found in the colon or rectum that can be precursors to colorectal cancer--will be randomly assigned to receive daily selenium supplements or a placebo for 3 or 5 years.